Abstract:Background and Aims Blood metabolite abnormalities have revealed an association with cholestatic liver diseases (CLDs), while the underlying metabolic mechanisms have remained sluggish yet. Accordingly, the present evaluation aims to investigate the causal relationship between blood metabolites and the risk of two major CLDs, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Methods Univariable and multivariable Mendelian randomization (MR) approaches were employed to uncover potential causal associations between blood metabolites and 2 CLDs, including PBS and PSC, through extracting instrumental variables (IVs) for metabolites from genome-wide association studies (GWAS) conducted on European individuals. The GWAS summary data of PBC or PSC were sourced from two distinct datasets. The initial analysis employed inverse variance weighted (IVW) and an array of sensitivity analyses, followed by replication and meta-analysis utilizing FinnGen consortium data. Finally, a multivariable MR analysis was carried out to ascertain the independent effects of each metabolite. Furthermore, the web-based tool MetaboAnalyst 5.0 was used to perform metabolic pathway examination. Results A genetic causality between 15 metabolites and CLDs was recognized after preliminary analysis and false discovery rate (FDR) correction. Subsequently, 9 metabolites consistently represented an association through replication and meta-analysis. Additionally, the independent causal effects of 7 metabolites were corroborated by multivariable MR analysis. Specifically, the metabolites isovalerylcarnitine (odds ratio [OR] = 3.146, 95% confidence intervals [CI]: 1.471–6.726, p = 0.003), valine (OR = 192.44, 95%CI: 4.949–7483.27, p = 0.005), and mannose (OR = 0.184, 95%CI: 0.068–0.499, p < 0.001) were found to have a causal relationship with the occurrence of PBC. Furthermore, erythrose (OR = 5.504, 95%CI: 1.801–16.821, p = 0.003), 1-stearoylglycerophosphocholine (OR = 6.753, 95%CI: 2.621–17.399, p = 7.64 × 10 −5 ), X-11847 (OR = 0.478, 95%CI: 0.352–0.650, p = 2.28 × 10 −6 ), and X-12405 (OR = 3.765, 95%CI: 1.771–8.005, p = 5.71 × 10 −4 ) were independently associated with the occurrence of PSC. Furthermore, the analysis of metabolic pathways identified seven significant pathways in two CLDs. Conclusion The findings of the present study have unveiled robust causal relationships between 7 metabolites and 2 CLDs, thereby providing novel insights into the metabolic mechanisms and therapeutic strategies for these disorders.

Causal associations between gut microbiota and Cholestatic liver diseases: a Mendelian randomization study

The causal relationship between gut microbiota and end-stage liver disease: a bidirectional Mendelian randomization analysis

Causal associations between gut microbiota and primary biliary cholangitis: a bidirectional two-sample Mendelian randomization study

A Bidirectional Two-Sample Mendelian Randomization Using the Gut Microbiota to Reveal Potential Therapeutic Targets for Primary Sclerosing Cholangitis.

[Genome-wide Mendelian randomization study of the pathogenic role of gut microbiota in benign biliary tract diseases]

Association between gut microbiota and autoimmune cholestatic liver disease, a Mendelian randomization study

Causal associations between human gut microbiota and cholelithiasis: a mendelian randomization study

Causal Linkage Between Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Two-Sample Mendelian Randomization Analysis

The Causality Between Gut Microbiome and Liver Cirrhosis: a Bi-Directional Two-Sample Mendelian Randomization Analysis

Bidirectional Mendelian randomization links gut microbiota to primary biliary cholangitis

Gut microbiota causally affects cholelithiasis: a two-sample Mendelian randomization study

Association between gut microbiota and hepatocellular carcinoma and biliary tract cancer: A mendelian randomization study

Elucidating the causal association between gut microbiota and intrahepatic cholangiocarcinoma through Mendelian randomization analysis

Causal relationship between gut microbiota and gastrointestinal diseases: a mendelian randomization study

Association of Gut Microbiome and Primary Liver Cancer: A Two‐sample Mendelian Randomization and Case–control Study

Gut microbiota and risk of ovarian diseases: a two-sample Mendelian randomization study

Causality of metabolites and metabolic pathways on cholestatic liver diseases: a Mendelian randomization study

Causal Relationship Between Gut Microbiota and Liver Cirrhosis: 16S rRNA Sequencing and Mendelian Randomization Analyses

Dissecting the association between gut microbiota and liver cancer in European and East Asian populations using Mendelian randomization analysis

Gut microbiota, circulating metabolites, and gallstone disease: a Mendelian randomization study

Causal roles of gut microbiota in cholangiocarcinoma etiology suggested by genetic study